According to a market report by Lucintel, the future of the global cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications. The global cancer testing screening market is expected to reach an estimated $214 billion by 2030 from $159 billion in 2024 at a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.
A more
than 150-page report to understand trends, opportunity and forecast in cancer
testing screening market to 2030 by technique (imaging, biopsy, genomic and
molecular tests, next generation sequencing, RT-PCR, microarrays, biomarker
testing, and others), cancer type (respiratory system cancer, leukemia, myeloma
and lymphoma, skin cancer, abdominal/digestive system cancer, urinary system
cancer, endocrine system cancer, breast cancer, and others), application
(hospitals, clinics, diagnostic centers, research institutes, and others), end
use (patients, healthcare providers, diagnostic laboratories, research
institutes, and pharmaceutical companies), and region (North America, Europe, Asia
Pacific, and the Rest of the World).
Lucintel
forecasts that biopsy is expected to witness highest growth over the forecast
period due to its great accuracy in the diagnosis of cancer.
Hospital
is expected to witness highest growth over the forecast perioddue to rising
patients preference for this facility for their treatment given to the
availability of well established infrastructure and presence of medical
expertise.
Download
sample by clicking on cancer
testing screening market.
North
America is expected to witness highest growth over the forecast period due to
constant increase in instances of prostate and lung cancer cases in the region.
Diasorin,
Immunodiagnostic Systems, Epigenomics, Quest Diagnostics, F. Hoffmann-La Roche,
VolitionRX, Abbott Laboratories, QIAGEN, Siemens Healthineers are the major
suppliers in the cancer testing
screening market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment